Mats Jerkeman
161 – 170 of 202
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Geisler, Christian H. ; Kolstad, Arne ; Laurell, Anna ; Raty, Riikka ; Jerkeman, Mats LU ; Eriksson, Mikael LU
; Nordstrom, Marie
; Kimby, Eva
; Boesen, Anne Marie
and Nilsson-Ehle, Herman
, et al.
(2010)
In Blood
115(8).
p.1530-1533
- Contribution to journal › Article
-
Mark
Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose Dense Chemoimmuno therapy and CNS Prophylaxis Results From a Nordic Lymphoma Group Phase II Study
(2010) 52nd Annual Meeting of the American-Society-of-Hematology (ASH) In Blood 116(21). p.1281-1281
- Contribution to journal › Published meeting abstract
-
Mark
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
- Contribution to journal › Article
-
Mark
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
- Contribution to journal › Article
-
Mark
High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study
Riihuarvi, Sari ; Nyman, Heidi ; Holte, Harald ; Bjorkholm, Magnus ; Fluge, Oystein ; Pedersen, Lars Moller ; Jerkeman, Mats LU ; Eriksson, Mikael LU
and Leppa, Sirpa
(2010)
52nd Annual Meeting of the American-Society-of-Hematology (ASH)
In Blood
116(21).
p.1686-1686
- Contribution to journal › Published meeting abstract
-
Mark
SOX11 expression correlates to promoter methylatuion and regulates tumor growth in hematopoietic malignancies
Gustavsson, Elin LU ; Sernbo, Sandra LU ; Andersson, Elin LU ; Brennan, Donal ; Dictor, Michael LU ; Jerkeman, Mats LU ; Borrebaeck, Carl LU and Ek, Sara LU
(2010)
In Molecular Cancer
9(187).
- Contribution to journal › Article
-
Mark
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
- Contribution to journal › Article
-
Mark
Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples.
Andreasson, Ulrika LU
; Edén, Patrik
LU
; Peterson, Carsten
LU
; Högerkorp, Carl-Magnus
LU
; Jerkeman, Mats
LU
; Andersen, Niels
; Berglund, Mattias
; Sundström, Christer
; Rosenquist, Richard
and Borrebaeck, Carl
LU
, et al.
(2010)
In American Journal of Hematology
85(6).
p.418-425
- Contribution to journal › Article
- 2009
-
Mark
Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA
(2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology In Journal of Clinical Oncology 27(15).
- Contribution to journal › Published meeting abstract
-
Mark
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
- Contribution to journal › Article